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Abstract
Background: It is becoming increasingly recognized that weight and nutritional status can impact cancer survival.
We have previously shown that obese mice with syngeneic acute lymphoblastic leukemia (ALL) have poorer response
to chemotherapy treatment than control mice. We therefore investigated whether dietary intervention could improve
outcome from the most common pediatric cancer, ALL.
Methods: Diet-induced obese (DIO) mice raised on a 60% calories from fat diet and control mice were implanted with
syngeneic ALL cells. Some DIO mice were switched to the low-fat control diet. Survival from ALL was assessed without
or with chemotherapy treatment starting at the time of the diet switch. Cells from DIO mice before and after diet
switch were assessed by FACS for BrdU incorporation and phosphorylation status of AKT, S6K, and EIF2a. Similar
experiments were done with human ALL xenografts. Mouse and human ALL cells were cultured in media with 10%
or 5% fetal bovine serum, and sensitivity to chemotherapies assessed.
Results: DIO mice had poorer survival (17%) after vincristine monotherapy than control mice on a 10% low fat diet (42%;
n= 12/group; p = 0.09, log rank). However, switching obese mice to the low-fat diet prior to initiation of vincristine led to
dramatically improved survival (92%, p < 0.01 vs both other groups). In vitro, FBS restriction made murine and human ALL
cells more sensitive to vincristine. Interestingly, while serum restriction enhanced ALL sensitivity to dexamethasone and
L-asparaginase, dietary switch did not improve survival of DIO mice treated with either drug in monotherapy. Thus, it
appears that dietary intervention has a unique effect to improve ALL cell sensitivity to vincristine in vivo.
Conclusions: We report herein that a dietary intervention can improve ALL outcome in a preclinical model. Further work
is needed to identify the mechanisms of this effect and investigate potential impact on human leukemia in patients.
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Background
Obesity increases the incidence of many cancer types, and
obese cancer patients have a higher risk of mortality from
their disease [1]. In 2007, a retrospective review of two large
cohorts demonstrated that obesity at the time of diagnosis
increases risk of relapse in children with National Cancer
Institute/Rome High-Risk acute lymphoblastic leukemia
(HR-ALL) by 50% [2], a finding confirmed in meta-analysis
[3]. In a separate cohort, we reported that obese children
were 2.74 times more likely to be minimal residual disease
(MRD) positive [4], which portends increased relapse risk
and reduced event-free survival [5]. Moreover, recent stud-
ies show 1 in 3 children with ALL were overweight or obese
at diagnosis [6, 7].
Much attention has been given to the role of diet on
cancer outcomes. Meta-analysis has shown that cancer
survivors who maintain high quality diets have lower over-
all mortality, though no significant reduction in cancer
recurrence [8]. Less clear is whether dietary intervention
during cancer treatment might improve outcome. Caloric
restriction has garnered much attention in this realm, as it
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can potently reduce insulin-like growth factor 1 (IGF-1), a
stimulator of cellular metabolism through activation of the
PI3K/Akt/mTOR axis [9, 10]. Non-transformed cells
respond to this low nutrient state by downregulating
mTOR activity and entering a state of quiescence, which
can protect them from some chemotherapies; however,
cancer cells often exhibit constitutive activation of PI3K/
Akt/mTOR [11]. This constitutive activation cannot be
modulated by nutrient restriction, leading to retained or in-
creased chemosensitivity of cancer cells [12, 13]. Additional
mechanisms also likely contribute to the beneficial effects
of caloric restriction, including reduced fuel availability, re-
duction of inflammation, and lower oxidative stress [9, 14].
We have developed a mouse model which recapitu-
lates the clinical observation that obese children have
worse ALL outcome; high-fat diet-induced obese (DIO)
mice implanted with syngeneic ALL had a poorer sur-
vival outcome after treatment with either vincristine
(VCR) or L-asparaginase [15, 16]. However, whether the
effects of obesity on ALL outcome in mice or patients is
reversible remains unknown. While caloric restriction
has been shown to improve chemotherapy efficacy in
mouse models of solid tumors [12], it has not been
tested in the most common childhood cancer, acute
lymphoblastic leukemia. Therefore, we designed the
present study to test whether a dietary intervention
could improve ALL outcome in obese mice.
Methods
Cell culture
Murine pre-B ALL cells were previously isolated from a
BCR/ABL transgenic mouse (“8093 cells” [17]) and
transduced with GFP. Human leukemia cell lines in-
cluded BV173 (pre B Ph + ALL, ATCC) and Nalm-6 (B
cell precursor leukemia, ATCC). Cells were authen-
ticated by the University of Arizona Genetics core in
November 2016 and tested negative for mycoplasma.
Eight thousand ninety-three cells were cultured in
McCoy’s 5A media (Invitrogen), supplemented with
1 mM sodium pyruvate, 2 mM Glutamax, 10 μg/mL
gentamycin and either 5% or 10% FBS (Denville Scientific
or Omega Scientific). Human cell lines were cultured in
RPMI 1640 (Invitrogen), supplemented as above.
Chemotherapy sensitivity experiments were performed
over 72 h, with surviving viable cells counted by
blinded observers in triplicate using trypan blue exclu-
sion manually, or with a Countess II (ThermoFisher).
LAX7 cells are patient-derived ALL cells with normal
karyotype which were expanded by passage through
NSG mice (mice described below) and used for xeno-
graft [18]. Cells were cultured on OP-9 stroma cells
with αMEM supplemented with 20% FBS, 100 IU/mL
penicillin, and 100 μg/mL streptomycin.
Mouse models
High fat diet-induced obese (DIO) and control C57Bl/6J
mice were purchased from Jackson Laboratories (Bar
Harbor, MI, USA). Mice had been raised on either a 60%
(obese) or 10% (control) calories from fat diet (Research
Diets, D12492 and D12450B, respectively). Because
female mice do not become as significantly obese in this
model and are not available as DIO mice from Jackson
Laboratories, only male mice were used for these stud-
ies. Male NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)
are NOD/SCID IL2-receptor gamma chain knockout
mice commonly used for xenograft. NSG mice were
made obese using selective culling and a high-fat diet as
previously described [19].
ALL survival experiments
ALL implantation experiments were performed on DIO
and control mice at ~ 20 weeks of age. At this time,
10,000 GFP+ pre-B-cell ALL 8093 cells were implanted
retro-orbitally. 6 or 7 days after ALL implantation,
depending on the experiment, DIO mice were random-
ized to continue on their high-fat diet or switched to the
control diet (10% calories from fat, provided ad libitum).
In some experiments, monotherapy with vincristine
(0.5 mg/kg/week intraperitoneal) was started on day 7,
and this dose was adjusted for body weight each week.
Similar experiments were performed with L-asparaginase
(800 IU/kg/day, Monday–Friday) or dexamethasone
(8 mg/kg/day, Monday–Friday). In other experiments,
DIO and control NSG mice were implanted with LAX7
cells, and after a 17 day engraftment period, half of the
DIO mice switched to control diet. On day 18, treatment
with vincristine, L-asparaginase and dexamethasone
(same doses as above) was started and continued for
4 weeks. Mice in all survival experiments were moni-
tored daily for food intake and body weight, and onset
of progressive leukemia (paralysis, hunched posture,
palpable mass > 1 cm, poor grooming, etc.), at which
time they were euthanized.
Tissue harvesting and flow cytometry
In some experiments, mice were anesthetized with keta-
mine/xylazine and perfused with PBS for organ harvest
at various timepoints before and after ALL implantation.
When performing cell cycle analysis, mice were injected
with BrdU intraperitoneally 4 h prior to organ harvest.
Spleen and femurs were removed, and spleen pulp and
femoral marrow were extruded with red blood cell lysis
buffer (BD Biosciences, San Jose, CA, USA) for flow cy-
tometry. Red blood cell-free bone marrow and spleen
pulp were filtered through 40 μm cell strainers to create
single cell suspensions. Cells utilized for cell cycle ana-
lysis were processed according to the manufacturer’s
protocol (APC BrdU Flow Kit, BD Biosciences). Cells
Tucci et al. Cancer & Metabolism  (2018) 6:15 Page 2 of 8
not used for cell cycle analysis were fixed in 4% PFA at
37 °C for 10 min and then permeabilized in chilled
methanol for 30 min. Cells were washed and incubated
in Mouse Fc Block (BD Biosciences) for 15 min then in-
cubated for 1 h in the following fluorophore-conjugated
antibodies: pEIF2α(Ser51)-PE/Cy7, pAKT(Ser473)-A647,
pS6K(Thr412)-PE (Bioss USA, Boston, MA, USA). Cells
were analyzed using the LSR II Flow Cytometer (BD
Biosciences) in the CHLA Flow Cytometry Core. Cells
were initially gated to exclude DAPI-positive dead cells
and forward and side scatter to exclude debris. Gating
on GFP allowed analysis of ALL vs. host cells.
Data analysis
Kaplan Meier survival curves were generated and com-
pared using Cox regression. Food intake was measured
manually by mouse cage, and reported as daily averages
or three-day moving averages as described in results. Vi-
able cells and proportions of cells labeled with BrdU or
other antibodies were compared between diet switch
and DIO mice using two-sided, paired t-tests. EC50 was
calculated by fitting normalized dose-response data to
the equation: %viable cells ¼ 100
1þ10ðLogðdoseÞ−LogðEC50ÞÞ . All ana-
lysis was performed using GraphPad Prism and Micro-
soft Excel.
Results
Diet restriction sensitizes ALL cells to vincristine
To determine whether switching diet could improve ALL
treatment outcome, we implanted 16 DIO and 8
non-obese control mice with syngeneic ALL cells (day 0;
Fig. 1a). On day 7, half of the DIO mice were switched to
the low-fat control diet, while the rest were continued on
their regular diet (final n = 8 per group). Time to progres-
sive ALL was not affected by diet in these mice (Fig. 1b).
In other groups of mice, VCR was started on day 7, and
VCR dose adjusted weekly based on body weight. In this
experiment, DIO mice switched to the low-fat diet had
the best survival, which was significantly better than mice
maintained on the high-fat diet (p < 0.001), and even bet-
ter than control mice that had been raised on the low-fat
diet (p < 0.01; n = 6 repeated in two separate experiments
for final n = 12 per group; Fig. 1c). Overall survival at the
end of the experiment was 92% in the diet-switch group,
42% in the control group and 17% in the DIO group.
Diet-switched mice in additional experiments exhibited
rapid weight loss, where their body weight declined to
match those of the control mice within approximately
6 days (Fig. 1d). This was associated with a substantial de-
cline in food intake, despite access to ad libitum feed.
Switched mice reduced food intake for several days after
the diet switch, leading to substantially decreased intake
of total calories, protein and fat (Fig. 1e). There was a
relative sparing of carbohydrate intake, due to the in-
creased carbohydrate density of the control diet. After a
couple of weeks, food intake in the switched mice in-
creased, and nutrient intake became similar to that of
controls.
Dietary restriction in animals leads to a large number
of hormonal, physical, physiologic, and metabolic
changes that cannot be completely modeled in vitro.
However, FBS restriction can simulate some of the de-
cline in growth factors that are observed with caloric re-
striction and weight loss. Reducing FBS concentration
increased VCR cytotoxicity (Fig. 2a); however, FBS con-
centrations below 5% impaired cell growth and viability.
We therefore used 5% FBS, which did not affect their
proliferation rate but made them significantly more sen-
sitive to VCR (Fig. 2b, c). Similar VCR sensitization was
observed in human ALL cell lines as well, BV173 and
Nalm6 (Fig. 2d–f ).
Diet restriction does not alter ALL response to L-
asparaginase or dexamethasone in vivo
Similar ALL survival experiments were done as above,
but using L-asparaginase or dexamethasone monother-
apy starting on day 7. Diet switch had no detectible
effect on survival in these experiments (Fig. 3a, b). FBS
restriction did increase 8093 cell sensitivity to dexa-
methasone (EC50 9.1 ± 2.3 vs. 16.3 ± 3.7 nM, p = 0.02)
and tended to increase sensitivity to L-asparaginase
(EC50 0.80 ± 0.22 vs. 1.30 ± 0.21 IU/mL, p = 0.13; Fig. 3c, d),
but not to Ara-C or daunorubicin (Additional file 1: Figure
S1). In addition, survival experiments performed with hu-
man ALL xenografted NSG mice treated with a combin-
ation of vincristine, L-asparaginase, and dexamethasone
(VDL) showed that diet-restricted mice had no difference
in survival from DIO or control mice (Additional file 2: Fig-
ure S2). Thus, the effect of dietary restriction to sensitize
ALL to chemotherapy treatment in vivo appears to be rela-
tively specific to VCR.
Diet restriction does not alter cell cycle rate of host or
ALL cells
To investigate whether dietary restriction changes cell
sensitivity to VCR by altering ALL or host cell cycling
rate, cells were harvested from groups of DIO mice be-
fore or after diet switch, 4 hours after BrdU injections.
ALL and host cells were separated by FACS from
spleens and bone marrows of DIO mice on day 6 after
ALL implantation (before any diet switch), day 8 (1 day
after diet switch), or day 14 (7 days after diet switch).
The percentage of GFP+ ALL cells in S phase were de-
termined and compared to GFP-host cells (splenocytes
or marrow cells) from the same tissues. The percentage
of cells in S phase was higher in splenic ALL cells than
non-ALL cells, but similar between ALL and non-ALL
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cells from marrow (Additional file 3: Figure S3). Diet
switch did not significantly alter this percentage in either
cell type.
Diet restriction does not alter AKT signaling in host or
ALL cells
To determine how diet restriction might alter relevant
intracellular signaling pathways, spleen- and marrow-de-
rived cells from obese and obese-dieted mice (described
above) were labeled with antibodies for EIF2a/pEIF2a,
AKT/pAKT, and S6K/pS6K and analyzed by flow cytome-
try. ALL cells from both tissues showed higher phosphor-
ylation levels of these proteins than host cells in most
samples (Additional file 3: Figure S3), confirming the
higher metabolic rate in cancer cells. However, diet switch
had no significant effect on phosphorylation state of any
of these proteins in host or ALL cells.
Discussion
We report herein that switching obese mice from a
high-fat to a low-fat diet improves ALL survival with
vincristine treatment from 17 to 92%. This is the first
study of which we are aware testing a diet intervention
on treatment outcome from a hematological malignancy.
Other studies have evaluated whether dietary interven-
tion can affect treatment outcome of solid cancers.
Fig. 1 Dietary restriction improves obese leukemic C57BL/6J mouse survival after vincristine treatment. a Scheme showing diet intervention in
survival experiments. b Survival of mice with ALL in each diet group with no chemotherapy treatment (n = 12/group). c Survival of mice with ALL
in each diet group treated with VCR. ▼ indicate VCR doses. Vehicle-treated mice were distributed evenly between all three diet groups, and
were combined due to no difference in survival. N = 12/group; **p < 0.01, ***p < 0.001, log rank. d Body weight of mice on each diet. e Total (left),
carbohydrate (center), and fat (right) calorie daily intake in mice from each diet group. Intake is shown as daily average up until day 5 after the
diet switch, and as 3 point moving average thereafter, due to high day-to-day variability. Standard deviations reflect variance between 2 and 4
cages, not individual mice. Since protein content was identical between diets, the relative intake was proportional to total caloric intake and not
shown separately
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Fig. 2 Serum restriction sensitizes ALL to vincristine treatment. a Viable 8093 cells after 72 h in culture media with various concentrations of FBS,
alone, or with 10 nM VCR (n = 3). b Dose response of murine ALL 8093 cells cultured with VCR in 5 or 10% FBS (n = 4). c Viable 8093 cells after
culture alone or with 10 nM VCR (n = 7) ***p < 0.001, two-sided, paired t test. d EC50 values calculated from dose responses of vincristine with all
three cell lines; connecting lines show paired experiments. *p < 0.05, ***p < 0.001, two-sided, paired t test. e, f Dose response of human ALL cell
lines BV173 (e) and Nalm6 (f) with VCR in 5 or 10% FBS (n = 4)
Fig. 3 Diet restriction does not sensitize murine ALL cells to dexamethasone or L-asparaginase. a, b Survival of mice in each diet group treated
with dexamethasone (a, n = 5–6) or L-asparaginase (b, n = 6). c, d Viable cells after 72 h in culture media with 5 or 10% FBS, alone or with 70 nM
dexamethasone (c) or 2.5 IU/mL L-asparaginase (d), n = 3
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Switching DIO mice from a high-fat to low-fat diet,
similar to the present study, has been shown to improve
survival from melanoma in mice treated with dacarba-
zine [20]. Ketogenic diets, containing very low carbohy-
drates, are used for patients with intractable epilepsy
and cause decreases in blood glucose concentrations but
elevations in circulating free fatty acids and ketones [21].
These diets have been shown to have an anti-tumor ef-
fect in 12 separate murine cancer models [22] and are
being evaluated in patients. Fasting and short-term star-
vation has also been shown to improve treatment out-
come from a wide variety of solid tumors in mice [12].
How efficacious these diets will be in cancer patients re-
mains to be seen.
Our findings are consistent with retrospective data
which shows that reversing obesity may be associated
with improved ALL outcome in youth. Orgel et al. ob-
served that ALL patients who had spontaneously lost
weight and changed from obese to non-obese category
over their treatment had better outcome than those who
remained obese for > 50% of their treatment course [23].
Based on this observation, and our current findings, we
have launched a clinical intervention trial of mild dietary
restriction and increased physical activity in children
with newly diagnosed ALL (IDEAL Weight in ALL Trial;
NCT 02708108). This and similar studies are critical to
help determine which cancers respond to dietary inter-
ventions and which specific interventions work for
which cancers.
While we were unable to identify the mechanism
whereby dietary restriction improved ALL outcome in
our study, we did rule out some important mecha-
nisms. VCR cytotoxicity is cell cycle dependent, as op-
posed to L-asparaginase and dexamethasone, which
could explain why mice treated with dexamethasone
or L-asparaginase derived no survival benefit from a
dietary switch. However, we did not detect an effect of
dietary intervention on cell cycle of ALL or host cells
one or 7 days after diet initiation. We also found no
effect of diet intervention on the ALL or host cell ac-
tivity of pathways commonly evaluated for effects of
dietary intervention on cancer, though we did observe
an increased activity of these pathways in the cancer
cells vs. host cells. Lack of effect of diet on AKT or
S6K phosphorylation implies that our intervention
was not acting through IGF-1 or mTOR, respectively.
eIF2a phosphorylation is observed with amino acid
deprivation, oxidative stress, and unfolded protein re-
sponse [24], arguing against these potential mecha-
nisms of our dietary intervention. It is possible that
these signals may have mediated effects after 7 days,
which we would have missed with our experimental
design. Further, while these findings argue against
these pathways, we did not exhaustively rule them out,
which would require extensive additional experiments
and should be evaluated in future studies.
It is also possible that the protective effect of a dietary
switch is mediated in part by immunological mecha-
nisms. In the 2010 update to the well-known “Hallmarks
of Cancer,” four new principles were identified as vital to
carcinogenesis and cancer cell survival, one being eva-
sion of immune destruction [25]. In addition to their
direct cytotoxic effect, some chemotherapies have been
identified as inducers of immunogenic cell death,
whereby their mechanism of cytotoxicity invokes a host
T-cell-mediated immunologic response [26]. These in-
clude the anti-microtubule agents docetaxel and pacli-
taxel, as well as the anthracyclines, daunorubicin and
doxorubicin, and the anthracendione, mitoxantrone.
Interestingly, caloric restriction and short-term fasting
have been shown to improve T-cell anti-tumor reactivity
and reduce immune-suppressing T-regs. Combined,
these studies suggest that dietary restriction could syner-
gize with a certain subset of chemotherapies to augment
host anti-tumor response and improve treatment out-
comes. This would be consistent with our finding that
NSG mice, which lack immune systems, obtained no
benefit from the dietary switch. On another note, it is
particularly interesting that three of the other four iden-
tified immune inducers, daunorubicin, doxorubicin, and
mitoxantrone, are commonly used in primary and re-
lapse ALL chemotherapy regimens. These chemothera-
peutic agents were not studied in our current model but
should be tested in future studies.
Our study has several limitations. Perhaps our biggest
limitation is that we did not detect an effect of dietary
intervention in our human xenograft model. This limits
the degree to which our results may be directly translat-
able to human leukemia. The lack of effect in this model
could have been due to the triple chemotherapy regimen
used, which could have masked a small effect of vincris-
tine alone, to the immunodeficient state as discussed
above, or to other mouse strain differences. In any case,
dietary intervention in human xenograft models should
be further evaluated so that relevance to human
leukemia can be confirmed. Another limitation is that
we tested a relatively crude dietary intervention—switch-
ing DIO mice from a high-calorie/high-fat diet to a
lower-calorie/low-fat diet. This switch induced several
changes, including decreased calorie, protein, and fat in-
take, while sparing carbohydrate intake. These changes
undoubtedly altered the animals’ insulin sensitivity, cir-
culating growth factors, body composition, and fuel
availability. Indeed, another study which utilized a simi-
lar high-fat to low-fat diet switch in C57Bl/6 mice
showed a number of physiological effects, including
decreases in glucose and insulin, improvement in lipids
and free fatty acids, and decrease in several pro-
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inflammatory cytokines and adipokines [20]. This broad
range of effects may contribute to the efficacy of this
intervention, but at the same time makes identification
of specific mechanisms difficult. Thus, further study will
need to be done to determine which of these changes
and effects contribute to the improved survival. On the
other hand, murine obesity induced by a high-fat diet is
not completely analogous to human obesity, which is
generally associated with excess carbohydrate intake;
thus, utility of these models for this purpose may be lim-
ited. Finally, despite the large observed effect of dietary
intervention on vincristine efficacy, the mechanism be-
hind this effect remains elusive.
While treatment of childhood ALL has led to substantial
improvements in survival, there are still ~ 8% children
who relapse from this disease every year [27]. In addition,
children with certain ALL subtypes, adolescents and
adults, and obese patients are all at increased risk of
relapse and mortality. Given the substantial toxicity of
current chemotherapy regimens, it is important to investi-
gate alternative approaches to improve ALL outcome
without adding additional chemotherapy agents.
Conclusions
Switching obese mice with ALL from a high-fat to
low-fat diet substantially improved survival with VCR
treatment, though not with L-asparaginase or dexa-
methasone treatment. The finding that a dietary inter-
vention can improve ALL treatment outcome in a
preclinical model should be further studied so that its
potential benefit can be evaluated in both obese and
non-obese patients.
Additional files
Additional file 1: Figure S1. Serum reduction does not improve efficacy
of Ara-C or DNR in vitro. A–C Viable 8093 (A), BV173 (B), and Nalm6 (C) cells
after 72 h exposure to chemotherapy Ara-C (left) or DNR (right) N = 4.
(TIF 979 kb)
Additional file 2: Figure S2. Dietary restriction does not affect ALL
outcome in xenograft NSG model treated with vincristine, dexamethasone,
and L-asparaginase (VDL). Obese-dieted n= 8, obese n= 6, control n= 5.
(TIF 183 kb)
Additional file 3: Figure S3. Effect of dietary restriction on host and
ALL cell cycle and Akt pathway activation. A Percentage of BrdU+
non-ALL and ALL cells from spleens (left) and marrow (right) of DIO
mice after ALL implantation on day 6 (1 day before diet switch), day 8
(1 day after diet switch), and day 14 (7 days after diet switch; n = 3).
B–D Phosphoprotein levels from flow cytometry of pS6K (B), pAKT (C),
and pEIF2α (D) from cells described in A. (TIF 130 kb)
Abbreviations
ALL: Acute lymphoblastic leukemia; DIO: Diet induced obesity;
DNR: Daunorubicin; EC50: Effective concentration that kills 50% of the cells;
FBS: Fetal bovine serum; MRD: Minimal residual disease; NSG: NOD/SCID IL2R
gamma chain knockout; VCR: Vincristine
Acknowledgements
The authors would like to thank Ehsan Ehsanipour for assistance in
performing these studies.
Funding
This work was supported by R01CA201444 (SDM), R01CA213129 (SDM),
R01CA172896 (YMK), and funds from The Saban Research Institute, CHLA.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
JT, WA, and TC designed and performed experiments, analyzed and
interpreted data, and helped in the preparation of the manuscript. XS helped
perform some experiments and develop flow cytometry experiments. YMK
provided patient sample cells and advised on xenograft model experiments.
SDM conceived of the experiments, oversaw all aspects of the study, and
wrote the manuscript. All authors approved the final manuscript.
Ethics approval
All studies were approved by the CHLA IACUC and performed in accordance





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Diabetes and Obesity Program, Center for Endocrinology, Diabetes and
Metabolism, Children’s Hospital Los Angeles, Keck School of Medicine,
University of Southern California, Los Angeles, CA, USA. 2Children’s Center for
Cancer and Blood Diseases, Children’s Hospital Los Angeles, Keck School of
Medicine, University of Southern California, Los Angeles, CA, USA. 3Present
Address: Cure 4 The Kids Foundation, Las Vegas, NV, USA. 4Division of
Pediatric Endocrinology, UCLA Children’s Discovery and Innovation Institute,
David Geffen School of Medicine UCLA, 10833 Le Conte Ave, Los Angeles,
CA 90095-1752, USA. 5Present Address: Aptose Biosciences, San Diego, CA,
USA.
Received: 26 July 2018 Accepted: 28 September 2018
References
1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity,
and mortality from cancer in a prospectively studied cohort of U.S. adults. N
Engl J Med. 2003;348(17):1625–38.
2. Butturini AM, Dorey FJ, Lange BJ, Henry DW, Gaynon PS, Fu C, et al. Obesity
and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007;
25(15):2063–9.
3. Orgel E, Genkinger JM, Aggarwal D, Sung L, Nieder M, Ladas EJ. Association
of body mass index and survival in pediatric leukemia: a meta-analysis. Am J
Clin Nutr. 2016;103(3):808–17.
4. Orgel E, Tucci J, Alhushki W, Malvar J, Sposto R, Fu CH, et al. Obesity is
associated with residual leukemia following induction therapy for childhood
B-precursor acute lymphoblastic leukemia. Blood. 2014;124(26):3932–8.
5. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et
al. Clinical significance of minimal residual disease in childhood acute
lymphoblastic leukemia and its relationship to other prognostic factors: a
Children’s Oncology Group study. Blood. 2008;111(12):5477–85.
6. Esbenshade AJ, Simmons JH, Koyama T, Koehler E, Whitlock JA, Friedman
DL. Body mass index and blood pressure changes over the course of
treatment of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer.
2011;56(3):372–8.
Tucci et al. Cancer & Metabolism  (2018) 6:15 Page 7 of 8
7. Orgel E, Mueske NM, Wren TA, Gilsanz V, Butturini AM, Freyer DR, et al. Early
injury to cortical and cancellous bone from induction chemotherapy for
adolescents and young adults treated for acute lymphoblastic leukemia.
Bone. 2016;85:131–7.
8. Schwedhelm C, Boeing H, Hoffmann G, Aleksandrova K, Schwingshackl L.
Effect of diet on mortality and cancer recurrence among cancer survivors: a
systematic review and meta-analysis of cohort studies. Nutr Rev. 2016;
74(12):737–48.
9. Meynet O, Ricci JE. Caloric restriction and cancer: molecular mechanisms
and clinical implications. Trends Mol Med. 2014;20(8):419–27.
10. Smith WJ, Underwood LE, Clemmons DR. Effects of caloric or protein
restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in
children and adults. J Clin Endocrinol Metab. 1995;80(2):443–9.
11. Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to
dietary restriction. Nature. 2009;458(7239):725–31.
12. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A,
et al. Fasting cycles retard growth of tumors and sensitize a range of cancer
cell types to chemotherapy. SciTranslMed. 2012;4(124):124ra127.
13. Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L, Longo VD. Fasting and
differential chemotherapy protection in patients. Cell Cycle. 2010;9(22):4474–6.
14. Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic
and molecular mechanisms. Trends Pharmacol Sci. 2010;31(2):89–98.
15. Behan JW, Yun JP, Proektor MP, Ehsanipour EA, Arutyunyan A, Moses AS, et
al. Adipocytes impair leukemia treatment in mice. Cancer Res. 2009;69(19):
7867–74.
16. Ehsanipour EA, Sheng X, Behan JW, Wang X, Butturini A, Avramis VI, et al.
Adipocytes cause leukemia cell resistance to L-asparaginase via release of
glutamine. Cancer Res. 2013;73(10):2998–3006.
17. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J.
Acute leukaemia in bcr/abl transgenic mice. Nature. 1990;344(6263):251–3.
18. Hsieh YT, Gang EJ, Geng H, Park E, Huantes S, Chudziak D, et al. Integrin
alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic
leukemia to chemotherapy. Blood. 2013;121(10):1814–8.
19. Behan JW, Ehsanipour EA, Sheng X, Pramanik R, Wang X, Hsieh YT, et al.
Activation of adipose tissue macrophages in obese mice does not require
lymphocytes. Obesity (Silver Spring). 2013;21(7):1380–8.
20. Malvi P, Chaube B, Singh SV, Mohammad N, Pandey V, Vijayakumar MV, et
al. Weight control interventions improve therapeutic efficacy of dacarbazine
in melanoma by reversing obesity-induced drug resistance. Cancer Metab.
2016;4:21.
21. Binkiewicz A, Sadeghi-Najad A, Hochman H, Loridan L, Senior B. An effect of
ketones on the concentrations of glucose and of free fatty acids in man
independent of the release of insulin. J Pediatr. 1974;84(2):226–31.
22. Klement RJ, Champ CE, Otto C, Kammerer U. Anti-tumor effects of
ketogenic diets in mice: a meta-analysis. PLoS One. 2016;11(5):e0155050.
23. Orgel E, Sposto R, Malvar J, Seibel NL, Ladas E, Gaynon PS, et al. Impact on
survival and toxicity by duration of weight extremes during treatment for
pediatric acute lymphoblastic leukemia: a report from the Children’s
Oncology Group. J Clin Oncol. 2014;32(13):1331–7.
24. Holcik M, Sonenberg N. Translational control in stress and apoptosis. Nat
Rev Mol Cell Biol. 2005;6(4):318–27.
25. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646–74.
26. Kepp O, Senovilla L, Kroemer G. Immunogenic cell death inducers as
anticancer agents. Oncotarget. 2014;5(14):5190–1.
27. Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg
H, de Bont E, et al. Successful therapy reduction and intensification for
childhood acute lymphoblastic leukemia based on minimal residual disease
monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin
Oncol. 2016;34(22):2591–601.
Tucci et al. Cancer & Metabolism  (2018) 6:15 Page 8 of 8
